Related Experiment Videos
Pseudohallucinations associated with moclobemide: a case report
1Department of Psychiatry and Psychotherapy, Georg-August University of Göttingen, Germany. ddegner@gwdg.de
Pharmacopsychiatry
|July 19, 2005
Summary
A patient experienced severe pseudohallucinations after starting moclobemide for depression. These adverse drug reactions resolved shortly after discontinuing the psychopharmacological medication.
Area of Science:
- Psychiatry
- Pharmacovigilance
- Neuroscience
Background:
- The Arzneimittelsicherheit in der Psychiatrie (AMSP) project monitors adverse drug reactions (ADR) in psychopharmacology.
- Understanding ADRs is crucial for patient safety in psychiatric treatment.
Observation:
- A 23-year-old male patient with a depressive episode was treated with moclobemide.
- Severe pseudohallucinations emerged six days after initiating moclobemide therapy.
Findings:
- The patient's pseudohallucinations resolved within two days of discontinuing moclobemide.
- This case highlights a potential adverse drug reaction associated with moclobemide treatment.
Implications:
- The findings underscore the importance of monitoring for unusual neurological or perceptual adverse drug reactions.
- Further investigation into the controversial nature of pseudohallucinations and their link to psychopharmacological agents is warranted.